硝酸镓（NSC #15200）治疗宫颈非鳞状细胞癌的II期试验。一项妇科肿瘤学组的研究。

A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.

作者信息

Malfetano J H, Blessing J A, Homesley H D

机构信息

Department of Obstetrics and Gynecology, Albany Medical College, NY 12208, USA.

出版信息

Am J Clin Oncol. 1995 Dec;18(6):495-7. doi: 10.1097/00000421-199512000-00008.

DOI:10.1097/00000421-199512000-00008

PMID:8526192

Abstract

A Phase II trial of gallium nitrate for patients with recurrent or metastatic nonsquamous cell carcinoma of the cervix was conducted by the Gynecologic Oncology Group (GOG) from March 1988 to January 1992. Twenty-six evaluable patients were treated with 750 mg/m2 of gallium nitrate every 3 weeks. Age range was 30-74 years with a median of 48 years. GOG performance status was 0-1 for all but four patients. Two patients had a complete response (7.7%), 1 patient had a partial response (3.8%), 13 patients had stable disease (50.0%), and 10 (38.5%) had increasing disease. The 95% confidence interval for response is 2.4-30.2%. The major toxicities were nausea, vomiting, and anemia. Gallium nitrate has modest activity in patients with nonsquamous cell carcinoma of the cervix.

摘要

1988年3月至1992年1月期间，妇科肿瘤学组（GOG）开展了一项针对复发性或转移性宫颈非鳞状细胞癌患者的硝酸镓II期试验。26例可评估患者每3周接受750mg/m²硝酸镓治疗。年龄范围为30 - 74岁，中位年龄48岁。除4例患者外，所有患者的GOG体能状态为0 - 1。2例患者完全缓解（7.7%），1例患者部分缓解（3.8%），13例患者病情稳定（50.0%），10例（38.5%）患者病情进展。缓解率的95%置信区间为2.4 - 30.2%。主要毒性反应为恶心、呕吐和贫血。硝酸镓对宫颈非鳞状细胞癌患者有一定活性。